News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

CoreValve, Inc. Announces that more than 1,000 High-risk Patients have been Treated with its ReValving(R) System for Percutaneous Aortic Valve Replacement (PAVR)



5/15/2008 10:41:48 AM

IRVINE, Calif.--(BUSINESS WIRE)--CoreValve (www.corevalve.com) announced today that the expanded clinical evaluation of its ReValvingĀ® System for percutaneous aortic valve replacement (PAVR) in high-risk patients with aortic stenosis continues to enroll patients at an accelerating pace. These procedures can be performed under local anesthesia, without the need for surgical cutdown/repair, and without hemodynamic support or artificially accelerating the heart rate.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES